Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525478 | 0.92 | HPGD (0.50) | HSD17B10HPGDNPC1 | |
| SCHEMBL15317053 | 0.92 | HPGD (0.50) | HSD17B10HPGDNPC1 | |
| SCHEMBL10082580 | 0.92 | HPGD (0.50) | HSD17B10HPGDNPC1 | |
| SCHEMBL3188564 | 0.87 | HSD17B10 (0.55) | HSD17B10HPGDNPC1LMNANPSR1 | |
| SCHEMBL889059 | 0.87 | HSD17B10 (0.55) | HSD17B10HPGDNPC1LMNANPSR1 | |
| SCHEMBL231219 | 0.87 | HSD17B10 (0.55) | HSD17B10HPGDNPC1LMNANPSR1 | |
| SCHEMBL1199882 | 0.84 | NPC1 (0.39) | HSD17B10HPGDNPC1GPR119UCHL1 | |
| SCHEMBL4919669 | 0.81 | HSD17B10 (0.47) | PTPN2PTPN1PTPN6HSD17B10HPGD | |
| SCHEMBL5275535 | 0.81 | HSD17B10 (0.47) | PTPN2PTPN1PTPN6HSD17B10HPGD | |
| SCHEMBL7885175 | 0.79 | HPGD (0.48) | HSD17B10HPGDABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1966151-B1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORP (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| EP-1984331-B1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORP (US) | 2010-10-20 | — | — | EP | disclosed |
| US-7807672-B2 | Compounds that are ERK inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-2170893-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| WO-2008156739-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1966151-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | PTPN2 1161/4885PTPN1 705/4885PTPN6 1116/4885 |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | PTPN2 1022/4885PTPN1 692/4885PTPN6 1037/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | PTPN2 872/4885PTPN1 579/4885PTPN6 923/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | PTPN2 872/4885PTPN1 579/4885PTPN6 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.